Per Stål

14.4k total citations · 4 hit papers
135 papers, 7.7k citations indexed

About

Per Stål is a scholar working on Epidemiology, Hepatology and Hematology. According to data from OpenAlex, Per Stål has authored 135 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Epidemiology, 65 papers in Hepatology and 23 papers in Hematology. Recurrent topics in Per Stål's work include Liver Disease Diagnosis and Treatment (65 papers), Liver Disease and Transplantation (28 papers) and Hepatocellular Carcinoma Treatment and Prognosis (28 papers). Per Stål is often cited by papers focused on Liver Disease Diagnosis and Treatment (65 papers), Liver Disease and Transplantation (28 papers) and Hepatocellular Carcinoma Treatment and Prognosis (28 papers). Per Stål collaborates with scholars based in Sweden, United States and Italy. Per Stål's co-authors include Rolf Hultcrantz, Hannes Hagström, Mattias Ekstedt, Stergios Kechagias, Patrik Nasr, Mats Fredrikson, Ulf Hammar, Johan Askling, Hans Glaumann and Greger Lindberg and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

Per Stål

130 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

2014 1.7k citations Mattias Ekstedt, Hannes Hagström et al. Hepatology profile →
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

2017 1.3k citations Mattias Ekstedt, Hannes Hagström et al. Hepatology profile →
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

2017 732 citations Hannes Hagström, Patrik Nasr et al. profile →
Decreased Survival of Subjects With Elevated Liver Function Tests During A 28-Year Follow-Up

2009 604 citations Per Stål, Rolf Hultcrantz et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Per Stål Sweden	35	6.0k	3.6k	2.2k	1.0k	948	135	7.7k
Anna Ludovica Fracanzani Italy	59	6.2k 1.0×	2.6k 0.7×	2.5k 1.1×	866 0.8×	1.1k 1.1×	217	9.4k
Paola Dongiovanni Italy	57	6.5k 1.1×	2.2k 0.6×	2.8k 1.3×	829 0.8×	1.1k 1.1×	188	9.1k
Yuichiro Eguchi Japan	40	4.8k 0.8×	3.0k 0.8×	1.6k 0.8×	701 0.7×	1.0k 1.1×	178	6.7k
Silvia Fargion Italy	62	7.3k 1.2×	3.1k 0.9×	2.9k 1.4×	1.2k 1.1×	1.1k 1.2×	267	11.6k
Marco Lenzi Italy	47	9.9k 1.6×	6.8k 1.9×	3.1k 1.4×	1.3k 1.2×	2.0k 2.1×	153	12.3k
Christian Datz Austria	43	3.1k 0.5×	2.0k 0.6×	822 0.4×	572 0.5×	597 0.6×	176	6.3k
Sébastien Dharancy France	37	4.6k 0.8×	3.4k 0.9×	1.2k 0.5×	1.8k 1.8×	1.9k 2.0×	159	6.7k
Hideyuki Hyogo Japan	42	4.4k 0.7×	2.2k 0.6×	1.9k 0.9×	769 0.7×	1.2k 1.3×	127	6.2k
Ran Oren Israel	30	2.6k 0.4×	1.6k 0.5×	1.4k 0.6×	476 0.5×	1.2k 1.3×	82	4.2k
Sven Francque Belgium	48	7.3k 1.2×	3.2k 0.9×	2.9k 1.3×	801 0.8×	1.5k 1.6×	194	9.1k

Countries citing papers authored by Per Stål

Since Specialization

Citations

This map shows the geographic impact of Per Stål's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Stål with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Stål more than expected).

Fields of papers citing papers by Per Stål

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Stål. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Stål. The network helps show where Per Stål may publish in the future.

Co-authorship network of co-authors of Per Stål

This figure shows the co-authorship network connecting the top 25 collaborators of Per Stål. A scholar is included among the top collaborators of Per Stål based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per Stål. Per Stål is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cai, Curtis, Daniela Nascimento Silva, Ola B. Nilsson, et al.. (2025). Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation. Gut. 74(7). 1125–1136.

Armasu, Sebastian M., Irene K. Yan, Fowsiyo Ahmed, et al.. (2025). Associations of S-Adenosylmethionine and S-Adenosylhomocysteine with Hepatocellular Carcinoma. Metabolites. 15(11). 740–740.

Armasu, Sebastian M., Irene K. Yan, Fowsiyo Ahmed, et al.. (2025). Association of Epigenetic Aging Biomarkers With Risk of MASLD ‐Related HCC. Liver International. 46(1). e70464–e70464.

Finn, Richard S., Masatoshi Kudo, Ivan Borbath, et al.. (2024). Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study.. Journal of Clinical Oncology. 42(16_suppl). 4100–4100. 2 indexed citations

Bergquist, Annika, Mattias Ekstedt, Hannes Hagström, et al.. (2024). Forty years of successful national research collaboration in liver disease – the Swedish experience. Scandinavian Journal of Gastroenterology. 59(12). 1314–1321. 1 indexed citations

Bremer, Birgit, et al.. (2024). Elevation of S2‐bound α1‐acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma. Journal of Viral Hepatitis. 31(7). 383–390. 1 indexed citations

Hagström, Hannes, et al.. (2023). Dysregulated peripheral proteome reveals NASH-specific signatures identifying patient subgroups with distinct liver biology. Frontiers in Immunology. 14. 1186097–1186097. 5 indexed citations

Rutkowski, Wiktor, Nikola Panić, Amir Mari, et al.. (2023). Non-alcoholic fatty pancreas disease and pancreatic exocrine insufficiency: pilot study and systematic review. Scandinavian Journal of Gastroenterology. 58(9). 1030–1037. 3 indexed citations

Engstrand, Jennie, Per Stål, Stefan Gilg, Anders Jansson, & C. Strömberg. (2023). Hepatocellular carcinoma in cirrhotic versus non-cirrhotic liver: Treatment and survival differences in a nationwide cohort. Scandinavian Journal of Surgery. 113(2). 120–130. 5 indexed citations

10.

Stål, Per, Patrik Nasr, Mattias Ekstedt, et al.. (2023). Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD. JHEP Reports. 6(2). 100915–100915. 16 indexed citations

11.

Gilg, Stefan, Ernesto Sparrelid, Jennie Engstrand, et al.. (2022). Molecular adsorbent recirculating system treatment in patients with post-hepatectomy liver failure: Long-term results of a pilot study. Scandinavian Journal of Surgery. 111(3). 48–55. 1 indexed citations

12.

Holmer, Magnus, Mattias Ekstedt, Patrik Nasr, et al.. (2022). Effect of common genetic variants on the risk of cirrhosis in non‐alcoholic fatty liver disease during 20 years of follow‐up. Liver International. 42(12). 2769–2780. 24 indexed citations

13.

Hagström, Hannes, Dawei Bu, Patrik Nasr, et al.. (2021). Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. Scandinavian Journal of Gastroenterology. 56(4). 437–442. 9 indexed citations

14.

Stål, Per, et al.. (2019). Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. Liver International. 39(6). 1098–1108. 66 indexed citations

15.

Hagström, Hannes, Patrik Nasr, Mattias Ekstedt, et al.. (2018). Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology. 17(6). 1148–1156.e4. 85 indexed citations

16.

Hagström, Hannes, Mats Fredrikson, Simone Ignatova, et al.. (2016). Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. PLoS ONE. 11(12). e0167776–e0167776. 18 indexed citations

17.

Stål, Per & Rolf Hultcrantz. (2013). [Hereditary hemochromatosis--a common genetic disease].. PubMed. 109(46). 2097–9. 2 indexed citations

18.

Wåhlin, Staffan, Per Stål, René Adam, et al.. (2011). Liver transplantation for erythropoietic protoporphyria in Europe. Liver Transplantation. 17(9). 1021–1026. 48 indexed citations

19.

Venook, Alan P., et al.. (2010). SORAFENIB TREATMENT AND SAFETY PROFILE IN CHILD PUGH B PATIENTS CHARACTERIZED IN FIRST INTERIM RESULTS OF GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA AND OF ITS TREATMENT WITH SORAFENIB). Hepatology. 52(4). 1140. 1 indexed citations

20.

Stål, Per. (1999). Gastroesophageal Reflux in Healthy Subjects: Significance of Endoscopic Findings, Histology, Age, and Sex. Scandinavian Journal of Gastroenterology. 34(2). 121–128. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact